Moderna’s meant to be a red-hot growth stock. What on earth’s gone wrong? 

Moderna’s been anything but a high-flying growth stock in this investor’s portfolio. So is it high time he gave up on this one?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Middle-aged white man pulling an aggrieved face while looking at a screen

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When a growth company metamorphoses into something else over time, the stock returns can be substantial.

For example, Amazon started life as an online book store. Fast forward to today, books are a tiny fraction of the overall business. Much of Amazon’s value now comes from AWS, its cloud computing platform

Nvidia‘s another prime example of a company that’s transformed itself. Its graphics processing units (GPUs) were originally designed to improve computer game images, not power a global artificial intelligence (AI) revolution.

Should you invest £1,000 in Windward right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Windward made the list?

See the 6 stocks

Both stocks have delivered massive returns over the past 20 years.

Created with Highcharts 11.4.3Amazon + Nvidia PriceZoom1M3M6MYTD1Y5Y10YALL18 Jan 202018 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25www.fool.co.uk

I thought something similar could happen with Moderna (NASDAQ: MRNA). Its vaccines gained widespread recognition during the pandemic when they were deployed to combat the Covid virus. However, the underlying mRNA technology has far-reaching potential beyond Covid, with applications that include vaccines for HIV, respiratory syncytial virus (RSV), and even personalised cancer treatments.

Alas, that investment case is looking threadbare right now, with Moderna stock falling 66% in the past 12 months. It took another 16% tumble on 13 January, adding insult to my already badly injured holding.

What’s gone wrong with this supposed growth stock? Let’s dig in.

Created with Highcharts 11.4.3Moderna PriceZoom1M3M6MYTD1Y5Y10YALL18 Jan 202018 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

Falling sales

The big problem is that Moderna’s revised its sales forecasts downward multiple times in recent months. It was at it again this week, when management lowered its 2025 sales guidance by $1bn.

It now sees revenue landing between $1.5bn and $2.5bn, rather than its previous September guess of $2.5bn to $3.5bn. For context, it achieved around $3bn in product sales last year.

These incredibly wide ranges tell us that the firm hasn’t really the foggiest about true demand for its two vaccines (Covid and RSV for adults aged 60 years and older). Whether because of vaccine fatigue or misinformation, less people are getting inoculated.

The firm had originally intended to break even on an operating cash basis by 2026. Then it was pushed back to 2028. Now, with sales still under huge pressure, even that might prove optimistic. Actual profits appear a distant prospect.

Some good bits

On the plus side, the firm’s identified cost reductions of $1bn this year and $500m in 2026. It expects to finish 2025 with about $6bn in cash. So Moderna isn’t in any immediate existential danger.

CEO Stéphane Bancel said: “We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business.”

It’s encouraging that Moderna’s still aiming to deliver up to 10 new products over the next three years, including three approvals this year. This includes potentially expanding its RSV vaccine to younger patients and a flu/Covid combination vaccine.

Should I sell?

I thought Moderna would use its pandemic windfall to rapidly diversify always from Covid sales before they evaporated. This hasn’t happened yet, and its new RSV vaccine’s struggling to get off the ground.

Looking ahead, there’s still Moderna’s late-stage personalised cancer vaccine, in development with Merck. This was shown to reduce melanoma spreading, or death, by 62% when combined with Merck’s Keytruda therapy. The companies have quickly expanded their research to other types of cancer. 

These cancer vaccines could still be revolutionary, so I’m going to keep holding my shares.

But there may be an even bigger investment opportunity that’s caught my eye:

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Ben McPoland has positions in Moderna. The Motley Fool UK has recommended Amazon, Moderna, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »